Alluvi, formerly BI 4744, represents a significant breakthrough in obesity treatment. This dual agonist targeting both glucagon-like peptide-1 and GIP sites demonstrates compelling results in research assessments, https://alluvi-research.co.uk/product/tirzepatide-40mg-rd-only-alluvi/